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| INTRODUC TI ON
β 2 -Glycoprotein I (β 2 -GPI) is a plasma glycoprotein comprising 326 amino acids arranged in five consensus repeat domains. 1 The first four domains of β 2 -GPI each contain 60 amino acids, whereas the fifth domain contains an extra 22 amino acids with a lysine-rich positively charged region at the C-terminal extension. 2 β 2 -GPI displays multiple effects in antiphospholipid syndrome, autoimmune disorders, vascular thrombosis, coagulation cascade, and oxidative stress. [3] [4] [5] [6] [7] [8] Nevertheless, the exact role of each β 2 -GPI domain and its structure-function relationships remains unclear.
We previously showed that β 2 -GPI plays an essential role in the suppression of vascular endothelial cell growth, cell migration, and angiogenesis under the regulation of nuclear factor-kappa B (NF-кB) signaling and vascular endothelial growth factor (VEGF)-mediated phosphorylation of VEGFR2, ERK1/2 and Akt pathways. [9] [10] [11] It is well established that abnormal cell migration and proliferation are closely related to carcinogenesis. [12] [13] [14] [15] Furthermore, many studies have reported that inhibition of cell migration decreases tumor growth in multiple cancers. [16] [17] [18] Therefore, it is important to elucidate the cellular basis and molecular mechanisms of β 2 -GPI function in antitumorigenesis. The present study aims to explore the specific regulatory domain and intracellular signaling of β 2 -GPI with a potential for antimelanoma progression.
Melanoma is one of the most prevalent cancers and the incidence rate of melanoma skin cancer is increasing worldwide. [19] [20] [21] Therefore, development of new strategies to prevent and treat melanoma is crucial. The present study investigated the function and structural characteristics of purified β 2 -GPI and its recombinant polypeptides in melanoma cell migration, proliferation and invasion, as well as the effects on melanoma growth in vivo. We also identified the specific amino acid residues of β 2 -GPI involved in the inhibition of melanoma cell malignancy. This is the first study to show that purified β 2 -GPI and its D1 domain inhibit melanoma cell migration, proliferation, and invasion in vitro and reduce melanoma growth in vivo. Moreover, the amino acid residues within the D1 domain for the function of anti-melanoma cell migration was also determined. This study has advanced our knowledge of the structure-function relationship of β 2 -GPI D1 in control of melanoma development.
| MATERIAL S AND ME THODS

| Cell culture
B16-F10 murine melanoma cells were purchased from the Bioresource Collection and Research Center, Taiwan and cultured in DMEM supplemented with 10% heat-inactivated FBS and 1%
penicillin/streptomycin/amphotericin B. Cells were seeded in 6-well plates at a density of 1.8 × 10 5 cells/well and treated with the indicated concentrations of purified β 2 -GPI, recombinant D1, D4, D5, D1234, and D12345 polypeptides, Fc vector, and BSA (control). All B16-F10 cells were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
| Purification of β 2 -GPI and recombinant β 2 -GPI polypeptides
β 2 -Glycoprotein I was purified from human plasma using an established protocol. 9 Briefly, plasma β 2 -GPI was isolated by 3% perchloric acid precipitation followed by heparin-sepharose affinity chromatography (HiTrap Heparin; GE Healthcare Bio-Sciences, Marlborough, MA, USA). Purity of β 2 -GPI was confirmed by SDS-PAGE and western blot analysis.
A Bac-to-Bac Baculovirus Expression System (Thermo Fisher Scientific, Waltham, MA, USA) was used to obtain baculovirus expressing recombinant β 2 -GPI polypeptides. Human β 2 -GPI cDNAs were cloned into a modified pFastBac1 vector using sense primers with an SpeI restriction site and antisense primers with a KpnI restriction site (primer sequences are shown in Table S1 ). Figure S1A provides details of the β 2 -GPI-expressing constructs. The N-terminal dual tag was removed by TEV protease cleavage. Baculovirus stocks expressing β 2 -GPI were used to infect SF9 insect cells according to the manufacturer's procedures (Life Technologies, Thermo Fisher Scientific).
Expressed polypeptides were purified by affinity purification using a Protein A column (Agarose bead technologies, Doral, FL, USA).
The purity of recombinant polypeptides was verified by Coomassie
Brilliant blue staining as well as by western blot analysis ( Figure S1B ).
| Wound-healing assay
Wound-healing assays were carried out using the tip of a 1-mL micropipette to make a straight scratch on a confluent monolayer of B16-F10 cells in a 6-well plate. Then, the cells were rinsed twice using PBS before adding the indicated concentrations of purified β 2 -GPI, recombinant D1, D4, D5, D1234, and D12345 polypeptides at 0 and 24 hours. Representative images of melanoma cell migration were photographed using an inverted phase microscope (Model IX70; Olympus, Tokyo, Japan). For all treatments, the wound at 0 hour was assigned as 100% and was compared with the percentage of wound healing at 24 hours. Photographs were taken using more than three fields per well and ImageJ software was used to calculate wound areas.
| Transwell migration assay
A 24-well culture plate with a Millicell insert (Millipore, Burlington, MA, USA) was used to carry out transwell migration. A total of 5 × 10 4 B16-F10 cells were plated into inserts in 0.5 mL medium containing 2% FBS and incubated for 24 hours at 37°C. The lower chamber was filled with complete DMEM medium supplemented with 10% FBS to induce cell migration. Cells that had traversed the membrane were fixed with 4% paraformaldehyde for 15 minutes, washed once using PBS, and stained using 0.5% crystal violet for 45 minutes. To assess cell migration, photographs were taken in more than five fields per membrane. The cells were counted under a microscope and were analyzed using ImageJ software. Changes in cell migration were expressed as a percentage of the control group by at least three independent experiments.
| Cell proliferation assay
B16-F10 cells were seeded at a density of 1. 
| Cell invasion assay
Cell invasion assays were carried out using a 24-well culture plate 
| Western blot analysis
Western blot analysis was carried out as previously described. 11 In brief, cells were lysed in RIPA buffer and cell extracts were separated by centrifugation at 12 000 g for 20 minutes at 4°C. Nuclear extracts were prepared for analysis of nuclear p50 and p65 levels.
The proteins were separated on a 10% SDS polyacrylamide gel and transferred to a PVDF membrane (Millipore). Immunoblots were blocked with 5% non-fat milk and then probed with primary antibodies against p-AKT, AKT p-ERK, ERK, p-p38, p38, p-JNK, JNK, β-actin, p-IKKα, IKKα, p-IκBα, IκBα, p50, p65, lamin A/C, and α-tubulin overnight at 4°C. After washing, transferred blots were incubated with HRP-conjugated secondary antibodies at room temperature for 2 hours. Bound IgG protein bands were visualized using an ECL detection system (BioRad Laboratories, Hercules, CA, USA) and quantified by densitometry using Image Quant software (Molecular Dynamics). Expression of each protein was normalized to the expression level of β-actin (for cytosolic proteins) or lamin A/C (for nuclear proteins). 7, and 9. On day 9, mice were killed and tumors were excised, photographed, and weighed.
| In vivo antitumor study
| Structural analysis
Sequence similarity between D1 and D2/D3/D4 polypeptides was assessed using a tool, ClustalW, based on their amino acid sequences and compared in terms of sequence conservation. 22 Information of conservation score was used to identify the conserved and nonconserved regions of the polypeptides. To explore the structural properties of β 2 -GPI D1, Dictionary of Secondary Structure of Proteins (DSSP) program 23 was used to calculate the solvent accessible surface area (SASA) value and annotate the secondary structure (SS) classes based on amino acid residues obtained from Protein Data Bank, entry ID 1QUB. 24 The information obtained from SASA and SS showed the structural characteristics of β 2 -GPI D1, D2, D3, and D4 polypeptides.
Root mean square deviations (RMSD) analysis for the tertiary structures of fragments A and B were compared among different polypeptides using PyMol software (https ://www.schro dinger.com/suite s/pymol ), and the structural alignment between D2/D3, D2/D4, and D3/D4 was compared. Evolutionary conservation of β 2 -GPI D1 amino acid residues and electrostatic environment of target amino acids were analyzed using CONSURF software (http://consu rf.tau.ac.il). Similarity between amino acids was reflected in the substitutions matrix. 
| Immunofluorescence staining
B16-F10 cells (1 × 10 5 cells/mL) were grown on 18 mm 2 glass coverslips at 37°C under 5% CO 2 for 24 hours with or without purified-β 2 GP1
(200 μg/mL), and then fixed with 4% paraformaldehyde at room temperature for 10 minutes. After fixation, cells were washed with PBS buffer, and blocked with 5% BSA in PBS, then incubated with primary antibodies at 4°C overnight or incubated with 1 μg/mL DAPI at room temperature for 10 minutes. After washing with PBS buffer three times, secondary antibody was added and the coverslips were mounted on slides. The cells were visualized using an Olympus BX61 fluorescence microscope.
| Coimmunoprecipitation assay
B16-F10 cells were seeded in 10-cm dishes at a density of 
| Site-directed mutagenesis
Residue mutations of β 2 -GPI cDNA were constructed by PCR using the QuickChange Lightning site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's instructions. Table S2 shows the primers for cDNA synthesis and the corresponding amino acid residues used in site-directed mutagenesis. Each cDNA construct was confirmed by DNA sequencing.
F I G U R E 1 Purified β 2 -glycoprotein I (β 2 -GPI) and recombinant β 2 -GPI polypeptides contribute to anti-cell migration. B16-F10 melanoma cells were cultured in 6-well plates at a density of 1.8 × 10 5 cells/well and treated with the indicated concentrations of purified β 2 -GPI, recombinant D1, D4, D5, D1234, and D12345 polypeptides, Fc vector, and BSA (control) for 48 h. A, B16-F10 cells were scraped using a pipette tip (white dotted lines indicate the scratched edges) and the migrating cells were assessed by wound-healing assay at 0 and 24 h. Representative photographs are shown using the inverted phase microscope at 40× magnification. The wound areas were assessed between 0 and 24 h and are represented as the percentage of the control group (set as 100%). ***P < .001. B, The effects of purified β 2 -GPI and its recombinant polypeptides on antimelanoma cell migration were also determined by transwell migration assay. Graph shows changes in cell migration as a percentage of the control group. Data represent mean ± SEM of triplicates. **P < .01, ***P < .001
| Statistical analysis
Results are expressed as mean ± SEM of at least three independent experiments. Student's t-test was used to evaluate statistically significant differences between two groups. Statistical analyses between three or more groups were carried out using one-way ANOVA with Tukey's method as a post-hoc test. P < 0.05 was considered statistically significant.
| RE SULTS
| Purified β 2 -GPI and recombinant β 2 -GPI polypeptides suppress B16-F10 melanoma cell migration
We investigated the effects of the purified β 2 -GPI and recombinant polypeptides of full-length β 2 -GPI (D12345), β 2 -GPI domains I-IV (D1234), domain I (D1), domain IV (D4), and domain V (D5) on F I G U R E 2 Role of recombinant β 2 -glycoprotein I (β 2 -GPI) D1 polypeptide in the inhibition of melanoma cell migration. B16-F10 melanoma cells were cultured in 6-well plates and treated with or without the indicated concentrations of purified β 2 -GPI, recombinant D1 polypeptide, Fc vector, and BSA (control) for 48 h. A, Cells were scraped with a pipette tip (white dotted lines indicate the scratched edges) and the migrating cells were assessed by wound-healing assay. Representative photographs are shown using an inverted phase microscope at 40× magnification. The wound areas between 0 and 24 h were calculated and represented as a percentage of the control group (set as 100%). Graph shows the relative wound width. Data represent mean ± SEM (three individual experiments). **P < .01, ***P < .001. B, Transwell migration assays using B16-F10 cells at different doses of recombinant β 2 -GPI D1 polypeptide are shown. Changes in cell migration were also represented as a percentage of the control group. Data represent mean ± SEM of triplicates. ***P < .001
B16-F10 cell migration using wound healing ( Figure 1A 
| Purified β 2 -GPI and recombinant β 2 -GPI polypeptides inhibit cell proliferation and invasion
To confirm the suppression effect of β 2 -GPI on melanoma cell proliferation, cell numbers were counted after treating cells with purified β 2 -GPI and recombinant polypeptides for 24, 36, and 48 hours ( Figure 3A) , and DNA synthesis was assessed by BrdU incorporation assay after treating cells with the purified β 2 -GPI and polypeptides for 48 hours ( Figure 3B ). Cell growth rates of the β 2 -GPI, D1234, D12345, and D1-treated groups were slower than those of cells treated with D4 and D5 polypeptides for 24, 36, and 48 hours. Among the tested F I G U R E 3 Purified β 2 -glycoprotein I (β 2 -GPI) and recombinant β 2 -GPI D1 polypeptide contribute to anti-cell proliferation. B16-F10 melanoma cells were cultured and treated with purified β 2 -GPI, recombinant peptides, Fc vector, or BSA (control). A, Cell proliferation was determined using a cell counting assay and cell numbers were scored at 24, 36, or 48 h. B, Cell proliferation was assessed by BrdU incorporation at 24 h. C, B16-F10 melanoma cells were cultured and treated with the indicated concentrations of purified β 2 -GPI, recombinant peptides, Fc vector, and BSA (control) for 24 h by invasion analysis. Experiments were repeated three times. Representative images from one experiment are shown (top) and cell invasion was quantified (bottom). D, Invasion assay using B16-F10 cells at different doses of recombinant β 2 -GPI D1 polypeptide were assessed. Data represent mean ± SEM of three individual experiments. *P < .01, **P < .01, ***P < .001
polypeptides, D1 showed the most potent inhibition of cell proliferation as determined by cell counting and BrdU assays. Next, we assessed whether β 2 -GPI, D1234, D12345, and D1 reduced melanoma cell invasion using a Matrigel-coated invasion assay ( Figure 3C ). Cells treated with β 2 -GPI, D1234, D12345, and D1 showed lower levels of cell invasion compared with the D4 and D5 groups. Furthermore, β 2 -GPI D1 inhibited cell invasion in a dose-dependent way. Significant suppression was found in 125, 250, and 500 nmol/L D1-treated cells compared with control cells (P < .001) ( Figure 3D ). Our results indicate that D1 is the most potent recombinant polypeptide reducing proliferation and invasion in B16-F10 melanoma cells.
| Effects of β 2 -GPI and recombinant β 2 -GPI polypeptides on protein expression
To determine the underlying mechanisms regulated by β 2 -GPI and recombinant β 2 -GPI polypeptides, levels of protein expression were determined by western blotting analysis. As shown in Figure 4A , protein levels of p-Akt, p-ERK, and p-p38 were downregulated in cells treated with β 2 -GPI, D12345, and D1, whereas the expression of p-JNK was unchanged. Evaluating the NF-κB pathway components, we found that phosphorylation of IKKα and IκBα was significantly reduced by β 2 -GPI, D12345, and D1 treatment ( Figure 4B) . Additionally, nuclear level of p50 expression was also decreased in cells treated with D12345 and D1, but nuclear p65 expression was not affected.
| β 2 -Glycoprotein I and D1 polypeptide suppress melanoma growth in vivo
To validate the antitumor effects of β 2 -GPI protein in vivo, we use a syngeneic murine melanoma model to confirm the inhibitory effects of β 2 -GPI and its recombinant D1 polypeptide on tumor growth. Mice were killed and tumors were surgically removed for analysis. Tumor volume in the β2-GPI-, D12345-, and D1-treated groups was reduced to 38.4%, 41.8%, and 22.5%, respectively, compared with the control mice at day 9 after treatment ( Figure 5A ). Significant suppression of the tumor mass was found in β 2 -GPI and recombinant D1 groups ( Figure 5B ). Furthermore, tumors in the D1-treated mice grew much more slowly than those in the other treated mice. These results are in accordance with our findings in vitro.
F I G U R E 4
Effects of β 2 -glycoprotein I (β 2 -GPI) and its recombinant polypeptides on protein expression in B16-F10 cells treated with β 2 -GPI or recombinant polypeptides. Western blotting analysis for the expression of (A) p-AKT, AKT, p-ERK, ERK, p-p38, p38, p-JNK, and JNK and (B) p-IKKα, IKKα, p-IκBα, IκBα, and the nuclear levels of p50 and p65. β-Actin and lamin A/C were used as the cytosolic and nuclear protein loading control, respectively. α-Tubulin was used to rule out contamination of cytosolic protein in nuclear protein extraction. Representative gels are shown (left) and the intensity of protein bands normalized by the internal control was quantitated as relative protein expression using ImageQuant software (right). Data are presented as mean ± SEM of at least three independent experiments. *P < .05, **P < .01 vs control group
| Sequence-based comparison of the structure of D1 polypeptide and other β 2 -GPI domains
Amino acid sequences of the four domains of β 2 -GPI were aligned to analyze the structural characteristics of D1-D4 polypeptides ( Figure 6A ). respectively. It seems that D2 has the highest similarity (with lowest RMSD value) of structural conformation with D4. Sequence identity between human and mouse β 2 -GPI is 76.5% and the similarity between the two polypeptides is 87.2% ( Figure S3 ). This shows that the protein structure of human and mouse β 2 -GPI are highly conserved.
| Validation of the hotspots in fragments A and B of D1 polypeptide
Based on the results of structural comparisons between D1 and D2/D3/D4 polypeptides, five amino acids P11, P17, K19, M42 and I55 in fragments A and B of the D1 polypeptide were proposed as Figure 7A shows that the five amino acids are located in the coil regions; however, P11 and P17 are close to the β2 strand, and M42 is close to the β5 strand in the D1 structure. I55 is the most variable among the five amino acids using evolutionary conservation analysis. In contrast, K19 is located in a conserved position ( Figure 7B ). Furthermore, all of the five amino acid residues are located in the surface area of the D1 tertiary structure ( Figure 7C ).
According to the electrostatic surface representation, P17, K19, M42
and I55 are shown to be located in a highly electropositive environment ( Figure 7D ), which may interact with the basic residues of other interacting proteins. 
| β 2 -Glycoprotein I and D1 polypeptide interact with annexin A2 in melanoma cells
To determine which protein is the counterpart molecule of β 2 -GPI, we determined the partner protein of β 2 -GPI by immunofluorescence staining, coimmunoprecipitation assay, and molecular docking approaches. Double immunofluorescence staining showed β 2 -GPI and anxA2 coexpression on the B16-F10 cell membrane ( Figure 8A ). Direct interaction between β 2 -GPI and anxA2 was further confirmed by coimmunoprecipitation assay as shown in Figure 8B . To define the possible binding site of β 2 -GPI D1 on the cell membrane, we used a molecular docking strategy to clarify several amino acid residues of D1 and found that P11, M42, and I55 residues allow a closer conformation distance with anxA2
( Figure 8C ). G250 and R284 residues of anxA2 are the closest counterpart toward D1 structure. However, mutation of P11, M42 and I55 residues disrupt the structural stability between β2-GPI D1 and anxA2. From analysis using the PIPER module of the Schrödinger Suite, binding affinity between mutated β2-GPI D1 and anxA2 was decreased to −18.13 kcal/mol after mutations of P11A, M42A, and I55P. As shown in Figure 8D , mutation of the three amino acid sites obviously diminished the hydrogen-bond interaction between β2-GPI D1 and anxA2. The structure-function relationship of the five selected amino acids was clarified further by site-directed mutagenesis. Mutation of P11A, M42A, and I55P reversed the cell migration ability of D1 on melanoma cell migration, whereas mutation of P17Y and K19T did not affect cell migration ( Figure 8E ). Therefore, P11A, M42A, and I55P residues are likely the key hotspots in the 
| D ISCUSS I ON
Several studies have characterized cell migration and proliferation in the progression of tumorigenesis. [12] [13] [14] [15] We showed previously that purified β 2 -GPI inhibits cell migration, proliferation, and angiogenesis in human aortic endothelial cells. [9] [10] [11] However, the role of natural β 2 -GPI in tumor development remains unknown. The present study showed that β 2 -GPI is a negative regulator of cell migration, proliferation, and invasion in melanoma cells. Furthermore, we analyzed the structure-function relationship of different β 2 -GPI domains involved in the control of tumor development.
It has been shown that the N-terminal domains of β 2 -glycoprotein I (DI-IV) inhibit VEGF-and basic fibroblast growth factor-induced angiogenesis in human umbilical vein cells. 26 However, domain V at the C-terminus differs from DI-IV in that it is critical for phospholipid binding. 27, 28 The plasmin-nicked form of β 2 -GPI was also identified to have antiangiogenic effects in endothelial cells. 29 Recently, enhanced microvessel formation and melanoma tumor growth were identified in β 2 -GPI-deficient mice. 30 To determine the precise role of β 2 -GPI in the regulation of melanoma cell migration, cell proliferation, and tumor growth, we carried out in vitro and in vivo experiments using purified β 2 -GPI and its recombinant peptide domains. Alterations of AKT, ERK1/2, p38, and NF-κB activation are known in tumorigenesis. [31] [32] [33] [34] We thus expect that β 2 -GPI and D1 polypeptide may regulate these signaling pathways and consequently inhibit melanoma cell migration, cell proliferation, and tumor growth.
In a previous study, anxA2 was reported to bind with β 2 -GPI in patients with cerebral venous thrombosis. 35 Clinical studies have shown that anxA2 is highly expressed in different tumor types. 36, 37 Accordingly, recent reports have shown the functional role for anxA2 in regulation of cell adhesion, migration, and invasion. 38, 39 In the present study, binding of β 2 -GPI to anxA2 was confirmed by immunofluorescence and coimmunoprecipitation assays. Furthermore, interaction between specific amino acids of β 2 -GPI D1 and anxA2
was shown by the molecular docking approach. Although anxA2 may be considered a molecular target of β 2 -GPI in melanoma cells, the clinical implications of our findings remain elusive. Further studies are needed to determine the exact mechanism of β 2 -GPI-mediated anxA2 regulation in melanoma progression. Both molecular simulation and site-directed mutagenesis assays provide us with coincident evidence for the essential amino acid residues of D1 polypeptide, which may trigger intracellular signaling pathways and consequently modulate tumor malignancy. An additional possibility is that other amino acid residues on the tertiary surface of β 2 -GPI also interact with membrane receptors other than anxA2, which could contribute to the prevention of cancer progression. Future work is needed to address these possibilities.
Taken together, this study shows the molecular basis of the structure-function relationship between D1 polypeptide and melanoma progression. The combination of structural, biochemical, and functional insights presented here provides strong expectation that D1
of β 2 -GPI may represent a new medication warranting further preclinical investigation for anticancer therapy.
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